ChemicalBook > CAS DataBase List > Tabituximab
Tabituximab
- Product Name
- Tabituximab
- CAS No.
- 1644134-10-0
- Chemical Name
- Tabituximab
- Synonyms
- Tabituximab;Research Grade Tabituximab;Research Grade Tabituximab (DHJ94801)
- CBNumber
- CB58081112
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Tabituximab Chemical Properties,Usage,Production
Uses
Tabituximab (OTSA101) is a humanized monoclonal antibody against frizzled class receptor 10 (FZD10)[1].
in vivo
Yttrium 90-radiolabeled OTSA101 (OTSA101-DTPA-90Y) shows significant antitumor activity following a single intravenous injection in mouse xenograft model[1].
References
[1] Blagodatski A, et al. Targeting the Wnt pathways for therapies. Mol Cell Ther. 2014 Sep 11;2:28. DOI:10.1186/2052-8426-2-28
Tabituximab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Tabituximab Suppliers
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24960
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9866
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7062
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11972
- Advantage
- 58
- Tel
- 18229892877 13823398779
- 3062105966@qq.com
- Country
- China
- ProdList
- 5348
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9798
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 9998
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6738
- Advantage
- 58
1644134-10-0, TabituximabRelated Search:
Zamerovimab
afelimomab
Navicixizumab
Apitegromab
Depatuxizumab
Flanvotumab
Mirzotamab
Adebrelimab
Fianlimab
Lampalizumab